Real-world effectiveness of nirmatrelvir-ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants

Lancet Infect Dis. 2023 Jun;23(6):639-640. doi: 10.1016/S1473-3099(23)00056-7. Epub 2023 Feb 10.
No abstract available

Publication types

  • Comment

MeSH terms

  • COVID-19 Drug Treatment
  • COVID-19*
  • Humans
  • Ritonavir / therapeutic use
  • SARS-CoV-2* / genetics

Substances

  • nirmatrelvir
  • Ritonavir

Supplementary concepts

  • SARS-CoV-2 variants